Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age
FM Russell, JR Carapetis, RL Burton, J Lin, PV Licciardi, A Balloch, L Tikoduadua, L Waqatakirewa, YB Cheung, MLK Tang, MH Nahm, EK Mulholland
Vaccine | ELSEVIER SCI LTD | Published : 2011
Awarded by U.S. NIAID
The authors wish to sincerely thank all the FiPP staff and families participating in the study, the Fiji Ministry of Health, CWMH paediatric department and laboratory and the many other people who contributed to the study including: Jane Nelson, Adam Jenney, Kathryn Bright, Samantha Colquhoun, Amanda O'Brien, Amy Auge, Katherine Gilbert, Evan Willis, Philip Greenwood, Beth Temple, Vanessa Johnston, Loretta Thorn, Porter Anderson, Brian Greenwood, George Siber, David Klein, Elizabeth Horigan, Farukh Khambaty and the DSMB members. Funding was provided by U.S. NIAID (grant numbers R01 AI 52337 and N01 AI-30021) and the Australian National Health and Medical Research Council. Pneumovax (TM) was kindly donated by CSL Biotherapies, Australia. The co-administered Tritanrix (TM)-HepB (TM) and Hiberix (TM) vaccines were kindly donated by GlaxoSmithKline. Clinical trials number NCT00170612.